SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor

Purpose: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR2285, the first oral coagulation factor XIa (FXIa) inhibitor developed in China in combination with aspirin, clopidogrel or ticagrelor in healthy subjects.Methods: This study was a single-center, randomized, d...

Full description

Bibliographic Details
Main Authors: Tingting Ma, Yanli Dong, Lei Huang, Yuanxun Yang, Yan Geng, Fei Fei, Pinhao Xie, Yu Zhao, Hui Lin, Zeyu Yang, Yun Jin, Xitong Ju, Runbin Sun, Juan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
anticoagulants
coagulation factor inhibitor
dual antiplatelet therapy
pharmacodynamics
pharmacokinetics
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1027627/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1027627/full

Similar Items